290 related articles for article (PubMed ID: 28681803)
21. Group A streptococcal vaccines: facts versus fantasy.
Steer AC; Batzloff MR; Mulholland K; Carapetis JR
Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
[TBL] [Abstract][Full Text] [Related]
22. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
23. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
Mansour NM; Abdelaziz SA
Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
[TBL] [Abstract][Full Text] [Related]
24. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.
Ozberk V; Pandey M; Good MF
Hum Vaccin Immunother; 2018; 14(8):2034-2052. PubMed ID: 29873591
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
[TBL] [Abstract][Full Text] [Related]
26. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
Batzloff MR; Fane A; Gorton D; Pandey M; Rivera-Hernandez T; Calcutt A; Yeung G; Hartas J; Johnson L; Rush CM; McCarthy J; Ketheesan N; Good MF
Hum Vaccin Immunother; 2016 Dec; 12(12):3089-3096. PubMed ID: 27541593
[TBL] [Abstract][Full Text] [Related]
27. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
[TBL] [Abstract][Full Text] [Related]
28. Changing epidemiology of acute rheumatic fever in the United States.
Lee GM; Wessels MR
Clin Infect Dis; 2006 Feb; 42(4):448-50. PubMed ID: 16421786
[No Abstract] [Full Text] [Related]
29. Immunity to group a streptococcal M proteins: forging a single-edged sword.
Madoff LC
Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
[No Abstract] [Full Text] [Related]
30. Variability in the distribution of genes encoding virulence factors and putative extracellular proteins of Streptococcus pyogenes in India, a region with high streptococcal disease burden, and implication for development of a regional multisubunit vaccine.
Sagar V; Bergmann R; Nerlich A; McMillan DJ; Nitsche Schmitz DP; Chhatwal GS
Clin Vaccine Immunol; 2012 Nov; 19(11):1818-25. PubMed ID: 22971782
[TBL] [Abstract][Full Text] [Related]
31. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
[TBL] [Abstract][Full Text] [Related]
32. Group A streptococcal meningitis: emm type distribution and theoretical vaccine coverage in children.
Tuerlinckx D; Gueulette E; Loens K; Goossens H; Smeesters PR
Acta Clin Belg; 2016 Jun; 71(3):138-41. PubMed ID: 26319426
[TBL] [Abstract][Full Text] [Related]
33. Host-pathogen interactions in Streptococcus pyogenes infections, with special reference to puerperal fever and a comment on vaccine development.
Areschoug T; Carlsson F; Stålhammar-Carlemalm M; Lindahl G
Vaccine; 2004 Dec; 22 Suppl 1():S9-S14. PubMed ID: 15576204
[TBL] [Abstract][Full Text] [Related]
34. Prospects for a group A streptococcal vaccine.
McMillan DJ; Chhatwal GS
Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
[TBL] [Abstract][Full Text] [Related]
35. emm Type distribution pattern of group A streptococcus in north India: need for a new preventive approach.
Dhanda V; Kumar R; Thakur JS; Chakraborti A
Indian J Med Res; 2010 Dec; 132(6):741-4. PubMed ID: 21245627
[No Abstract] [Full Text] [Related]
36. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate.
Guerino MT; Postol E; Demarchi LM; Martins CO; Mundel LR; Kalil J; Guilherme L
Vaccine; 2011 Oct; 29(46):8250-6. PubMed ID: 21907752
[TBL] [Abstract][Full Text] [Related]
37. Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors.
Byrd CM; Bolken TC; Jones KF; Warren TK; Vella AT; McDonald J; King D; Blackwood Z; Hruby DE
Vaccine; 2002 May; 20(17-18):2197-205. PubMed ID: 12009273
[TBL] [Abstract][Full Text] [Related]
38. Molecular heterogeneity among north Indian isolates of Group A Streptococcus.
Sagar V; Bakshi DK; Nandi S; Ganguly NK; Kumar R; Chakraborti A
Lett Appl Microbiol; 2004; 39(1):84-8. PubMed ID: 15189292
[TBL] [Abstract][Full Text] [Related]
39. Epidemic of group A Streptococcus M/emm59 causing invasive disease in Canada.
Tyrrell GJ; Lovgren M; St Jean T; Hoang L; Patrick DM; Horsman G; Van Caeseele P; Sieswerda LE; McGeer A; Laurence RA; Bourgault AM; Low DE
Clin Infect Dis; 2010 Dec; 51(11):1290-7. PubMed ID: 21034198
[TBL] [Abstract][Full Text] [Related]
40. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
